Scope. This article describes research publications. It does not establish that a particular product works and provides no usage instructions.

GHK-Cu identifies a specific complex

GHK is a tripeptide made of glycine, histidine and lysine. It can bind copper to form the complex commonly called GHK-Cu. That identity is more precise than the broad term ‘copper peptide’, which can encompass different ingredients and formulations.

In a product, the label name alone does not reveal the amount of intact complex, its stability, copper availability or whether it reaches a relevant layer of skin. Those are formulation and quality-control questions.

What cell studies show

An older study that is often cited observed stimulation of collagen synthesis in fibroblast cultures exposed to the complex. This kind of experiment is useful for exploring a mechanism and forming hypotheses.

A cell culture is not intact skin. It does not reproduce the skin barrier, whole-body metabolism or repeated use of a finished product. It therefore cannot establish that a cosmetic will create the same visible change in people.

Evidence level. A fibroblast response supports biological plausibility; it does not establish clinical cosmetic efficacy.

Wound models add context, not cosmetic certainty

Research in rat wound chambers examined connective-tissue accumulation after exposure to GHK-Cu. It provides information within a controlled model of tissue repair.

Experimental wound healing in an animal differs from healthy human skin and a desired change in appearance. Species, injury type, administration route and biological endpoints all limit translation.

Permeation depends on formulation

An in-vitro assessment using excised human skin compared movement of copper tripeptide from cosmetic formulations. It illustrates an essential point: including an ingredient and moving it across a barrier are different questions.

Even a permeation measurement does not establish clinical improvement. Researchers must still determine whether the complex remains intact, how much reaches its target, whether that exposure is reproducible and whether a human trial finds a meaningful effect with acceptable tolerability.

Evidence level. Results from one formulation should not be extended to every serum, cream or product carrying the GHK-Cu name.

How to assess a claim about GHK-Cu

A strong claim should identify the tested product, concentration, vehicle, comparator, duration, participant count and measurement method. Non-standardised photographs or testimonials do not replace those details.

A registered trial can show that human research is planned or under way, but a registry entry without results does not prove efficacy. In September 2026, the gap between mechanistic literature and product-specific clinical evidence remains the central question.

  • Does the result come from cells, animals, excised skin or human participants?
  • Is the tested item identical to the commercial formulation being presented?
  • Are the comparator and baseline clearly described?
  • Are adverse events and withdrawals reported?

Primary and official sources

  1. Maquart et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ (1988)
  2. Maquart et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds (1993)
  3. Pickart et al. Skin permeation of copper tripeptide from cosmetic formulations: an in vitro assessment (2010)
  4. ClinicalTrials.gov, topical GHK-Cu study, NCT07437586 (registry entry; no published results)